Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyethylene glycol loxenatide versus metformin for gut microbiota and metabolic outcomes in overweight adults with type 2 diabetes
ChiCTR2200057155Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Mar 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of polyethylene glycol loxenatide and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Beijing Hospital. Primary endpoints: Fecal gut microbiota abundance at week 16 and HbA1c at week 16. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
polyethylene glycol loxenatidemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200057155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057155.